Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Translational Neurodegeneration. 2019;8:9.

Article  PubMed  PubMed Central  Google Scholar 

Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY. Resolvins lipid mediators: potential therapeutic targets in Alzheimer and Parkinson disease. Neuroscience. 2022;507:139–48.

Article  CAS  PubMed  Google Scholar 

Antonazzo M, Botta M, Bengoetxea H, Ruiz-Ortega JA, Morera-Herreras T. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. Int Rev Neurobiol. 2019;146:229–57.

CAS  PubMed  Google Scholar 

Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem Pharmacol. 2018;157:67–84.

Article  CAS  PubMed  Google Scholar 

Basurco L, Abellanas MA, Ayerra L, Conde E, Vinueza-Gavilanes R, Luquin E, Vales A, Vilas A, Martin-Uriz PS, Tamayo I, Alonso MM, Hernaez M, Gonzalez-Aseguinolaza G, Clavero P, Mengual E, Arrasate M, Hervás-Stubbs S, Aymerich MS. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson’s disease. Glia. 2022;71:571–87.

Article  PubMed  PubMed Central  Google Scholar 

Bajaj S, Jain S, Vyas P, Bawa S, Vohora D. The role of endocannabinoid pathway in the neuropathology of Alzheimer’s disease: can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer’s disease? Brain Res Bull. 2021;174:305–22.

Article  CAS  PubMed  Google Scholar 

Baul HS, Manikandan C, Sen D. Cannabinoid receptor as a potential therapeutic target for Parkinson’s disease. Brain Res Bull. 2019;146:244–52.

Article  CAS  PubMed  Google Scholar 

Bentea E, Van der Perren A, Van Liefferinge J, El Arfani A, Albertini G, Demuyser T, Merckx E, Michotte Y, Smolders I, Baekelandt V, Massie A. Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated αsynuclein. Front Behav Neurosci. 2015;9:68.

Article  PubMed  PubMed Central  Google Scholar 

Bernardo A, Minghetti L. PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr Pharm Design. 2006;12:93–109.

Article  CAS  Google Scholar 

Björklund A, Mattsson B. (2024) The AAV-α-synuclein model of Parkinson’s disease: An update. J Parkinsons Dis, in press.

Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15:5372–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J. Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease. Molecules. 2019;24:2702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgaz S, García C, Gómez-Cañas M, Rolland A, Muñoz E, Fernández-Ruiz J. Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease. Molecules. 2021a;26:3245.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgaz S, García C, Gonzalo-Consuegra C, Gómez-Almería M, Ruiz-Pino F, Unciti JD, Gómez-Cañas M, Alcalde J, Morales P, Jagerovic N, Rodríguez-Cueto C, de Lago E, Muñoz E, Fernández-Ruiz J. Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis. Molecules. 2021b;26:7643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice. Mol Cell Neurosci. 2021c;110:103583.

Article  CAS  PubMed  Google Scholar 

Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. α-Synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.

Article  PubMed  PubMed Central  Google Scholar 

Carta AR, Pisanu A. Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson’s disease? Neurotox Res. 2013;23:112–23.

Article  CAS  PubMed  Google Scholar 

Castro-Sánchez S, García-Yagüe AJ, López-Royo T, Casarejos MJ, Lanciego JL, Lastres-Becker I. Cx3cr1-deficiency exacerbates α-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson’s disease. Glia. 2018;66:1752–62.

Article  PubMed  Google Scholar 

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS. GPR55: a therapeutic target for Parkinson’s disease? Neuropharmacology. 2017;125:319–32.

Article  CAS  PubMed  Google Scholar 

Chen C. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. Pharmacol Ther. 2023;244:108394.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chocarro J, Rico AJ, Ariznabarreta G, Roda E, Honrubia A, Collantes M, Peñuelas I, Vázquez A, Rodríguez-Pérez AI, Labandeira-García JL, Vila M, Lanciego JL. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates. Brain. 2023;146:5000–14.

Article  PubMed  PubMed Central  Google Scholar 

Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S, Park SH, Jin BK. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol. 2011;187:6508–17.

Article  CAS  PubMed  Google Scholar 

Coles M, Steiner-Lim GZ, Karl T. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease. Front NeuroSci. 2022;16:962922.

Article  PubMed  PubMed Central  Google Scholar 

Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñoz E. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease. Sci Rep. 2016;6:29789.

Article  PubMed  PubMed Central  Google Scholar 

Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta. 2014;1845:42–52.

CAS  PubMed  Google Scholar 

Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, Moratalla R. Beneficial effects of the phytocannabinoid ∆9-THCV in L-DOPA-induced dyskinesia in Parkinson’s disease. Neurobiol Dis. 2020;141:104892.

Article  CAS  PubMed  Google Scholar 

Fernández-Moncada I, Eraso-Pichot A, Dalla Tor T, Fortunato-Marsol B, Marsicano G. An enquiry to the role of CB1 receptors in neurodegeneration. Neurobiol Dis. 2023;184:106235.

Article  PubMed  Google Scholar 

Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol. 2009;156:1029–40.

Article  PubMed  PubMed Central  Google Scholar 

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol. 2011;163:1365–78.

Article  PubMed  PubMed Central